Financial Tearsheet

Company Overview

Recent Financial News

Date   Headline
Oct 11, 2018 Aytu BioScience Announces Issuance of First U.S. Patent Covering MiOXSYS(R) for Male Infertility; Company Progresses Toward U.S. Regulatory Clearance and Commercialization
Oct 10, 2018 Aytu BioScience Announces Closing of $15.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Oct 05, 2018 Aytu BioScience Announces Pricing of $13.2 Million Underwritten Public Offering
Sep 17, 2018 Aytu BioScience Announces Publication of Manuscript Summarizing Results from the Ongoing Natesto(R) Spermatogenesis Study
Sep 06, 2018 Natesto(R) Q4 Revenue Increases 178% Sequentially; Q4 Product Revenue Increases 52% Sequentially

IR Contacts

Hayden IR

James Carbonara
1441 Broadway
Fifth Floor
New York, NY 10018
Office: (646)-755-7412
James@haydenir.com

Stock Performance

Today's Open 1.23
Volume 213,414
Day Range 1.15 - 1.25
52 Week Range 0.23 - 6.96
Bid/Ask 1.20 / 1.25
Bid/Ask Size 7,000 X 100
Previous Close 1.21
Market Cap 2.21 million
Shares Outstanding 1.79 million
Dividend/Yield 0.00 / 0.00%
EPS (TTM) -57.495000
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Sep 06, 2018 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
May 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Feb 08, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Nov 09, 2017 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Oct 19, 2017 10-K/A Annual report (Amendment) htmlhtml   pdfpdf  

Management Team

Josh Disbrow, Chairman & Chief Executive Officer

Jarrett Disbrow, Chief Operating Officer

David Green, Chief Financial Officer

Board of Directors

Josh Disbrow, Chairman & Chief Executive Officer

Gary Cantrell, Director, Chair, Compensation Committee

Carl Dockery, Director, Chair, Nominating & Governance Committee

John Donofrio, Jr., Director, Chair, Audit Committee

Michael Macaluso, Director